Pseudomonas aeruginosa Clinical Trials

10 recruitingLast updated: May 11, 2026

There are 10 actively recruiting pseudomonas aeruginosa clinical trials across 27 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3. Top locations include New York, New York, United States, Montpellier, France, Austin, Texas, United States. Updated daily from ClinicalTrials.gov.


Pseudomonas aeruginosa Trials at a Glance

10 actively recruiting trials for pseudomonas aeruginosa are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in New York, Montpellier, and Austin. Lead sponsors running pseudomonas aeruginosa studies include BiomX Ltd, Centre Hospitalier Régional d'Orléans, and AstraZeneca.

Browse pseudomonas aeruginosa trials by phase

About Pseudomonas aeruginosa Clinical Trials

Looking for clinical trials for Pseudomonas aeruginosa? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pseudomonas aeruginosa trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pseudomonas aeruginosa clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Bronchiectasis With Pseudomonas Aeruginosa Colonization
AstraZeneca435 enrolled183 locationsNCT07088926
Recruiting

Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa

Pseudomonas aeruginosaPrognosisPseudomonas Infections+3 more
Centre Hospitalier Régional d'Orléans600 enrolled48 locationsNCT06738771
Recruiting

Pathobiomes in Gut of Critically Ill Patients

Pseudomonas aeruginosa
University of Chicago100 enrolled1 locationNCT06822465
Recruiting
Phase 1Phase 2

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Pseudomonas aeruginosaCystic Fibrosis LungRespiratory Infections, Recurrent, Chronic
Respirion Pharmaceuticals Pty Ltd72 enrolled22 locationsNCT06016088
Recruiting

Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies

Pseudomonas aeruginosaMulti-antibiotic Resistance
University Hospital, Grenoble30 enrolled1 locationNCT04335383
Recruiting
Phase 2

Study With Phage for CF Subjects With Pseudomonas Lung Infection

Cystic Fibrosis (CF)Chronic Pseudomonas Aeruginosa Infection
BiomX Ltd63 enrolled14 locationsNCT06998043
Recruiting
Not Applicable

A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis

Viral InfectionBronchiectasis with Acute ExacerbationBronchiectasis Adult+2 more
Imperial College London54 enrolled1 locationNCT06931002
Recruiting

Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa

OsteomyelitisPseudomonas aeruginosaBacterial Infections+1 more
Centre Hospitalier de Saint-Denis300 enrolled1 locationNCT07056881
Recruiting

Phenotypic and Genotypic Characteristics of Pseudomonas Aeruginosa Isolates in Sohag University Hospitals

Pseudomonas aeruginosa infection
Sohag University100 enrolled1 locationNCT06417593
Recruiting
Phase 3

Tolerability and Safety of Inhaled Colistimethate Sodium (CMS) Administered Once Daily Compared to Twice Daily Dosing in Adult and Adolescent Subjects with Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection (COPILOT)

Pseudomonas aeruginosa infectionCystic Fibrosis
Spexis Australia Pty Ltd38 enrolled1 locationACTRN12624000601538